The new facility will ‘improve security of supply’ and meet demand from patients across Europe.
The Dutch producer of medicinal cannabis is to open a new facility in Denmark in order to meet demand from patients across Europe.
Bedrocan, the sole producer of medicinal cannabis in the Netherlands since 2003, has announced it will establish a new facility to manufacture its products in Denmark.
The company says its new GMP-approved facility, located in Køge near Copenhagen, will allow it to expand production capacity to meet the growing international demand for its products.
Bedrocan’s products are used by patients on prescription and as pharmaceutical raw materials and active pharmaceutical ingredients by researchers and pharmaceutical companies in multiple countries around the world.
It currently operates two indoor production facilities, a plant research and development facility, and a laboratory in the Netherlands. However, under the current legal framework in Bedrocan’s products are only available via the Dutch Office of Medicinal Cannabis (OMC), which is part of the Ministry of Health.
With its Danish site, Bedrocan expects to significantly improve the availability of its products to patients globally, with the freedom to conduct business directly with other commercial entities.
The new facility is expected to be operational by the end of 2023, with around 40 staff on board.
It will begin with the production of known Bedrocan varieties, including Bedrocan and Bediol oil, plus a new high-CBD variety, with products initially intended to supply the European market.
